标题
Management of AL amyloidosis in 2020
作者
关键词
-
出版物
BLOOD
Volume 136, Issue 23, Pages 2620-2627
出版商
American Society of Hematology
发表日期
2020-12-02
DOI
10.1182/blood.2020006913
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Safety, Tolerability, and Response Rates of Daratumumab in Relapsed AL Amyloidosis: Results of a Phase II Study
- (2020) Vaishali Sanchorawala et al. BLOOD
- A prospective phase II of daratumumab in previously treated systemic light chain amyloidosis (AL) patients
- (2020) Murielle Roussel et al. BLOOD
- Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic range albuminuria
- (2020) Christoph Richard Kimmich et al. BLOOD
- Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis
- (2020) Oliver C. Cohen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study
- (2020) Suzanne Lentzsch et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis
- (2020) Rahma Warsame et al. Blood Cancer Journal
- Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA
- (2020) Giovanni Palladini et al. BLOOD
- A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis
- (2020) Surbhi Sidana et al. Blood Cancer Journal
- Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression
- (2020) Marco Basset et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
- (2020) Efstathios Kastritis et al. JOURNAL OF CLINICAL ONCOLOGY
- Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis
- (2019) Heather Landau et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Establishment of brain natriuretic peptide ‐ based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis
- (2019) Brian Lilleness et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria
- (2019) Faye A. Sharpley et al. HAEMATOLOGICA
- A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
- (2019) Richa Manwani et al. BLOOD
- Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis
- (2018) Richa Manwani et al. HAEMATOLOGICA
- Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time
- (2018) M Hasib Sidiqi et al. JOURNAL OF CLINICAL ONCOLOGY
- Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis
- (2018) Richa Manwani et al. HAEMATOLOGICA
- Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis
- (2018) Brian Lilleness et al. BLOOD
- Nonbiopsy Diagnosis of Cardiac Transthyretin AmyloidosisCLINICAL PERSPECTIVE
- (2016) Julian D. Gillmore et al. CIRCULATION
- Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category
- (2016) E Muchtar et al. LEUKEMIA
- Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience
- (2015) V. Sanchorawala et al. BLOOD
- Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens
- (2015) Tilmann Bochtler et al. JOURNAL OF CLINICAL ONCOLOGY
- Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone
- (2014) Tilmann Bochtler et al. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis
- (2014) L. Diomede et al. BLOOD
- A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
- (2014) G. Palladini et al. BLOOD
- Increased Serum Free Light Chains Precede the Presentation of Immunoglobulin Light Chain Amyloidosis
- (2014) Brendan M. Weiss et al. JOURNAL OF CLINICAL ONCOLOGY
- A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
- (2013) A. D. Wechalekar et al. BLOOD
- New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
- (2012) Giovanni Palladini et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
- (2012) Shaji Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started